guselkumab in active psoriatic arthritis participants with inadequate response/intolerance to one prior anti-tnf alpha agent

Conditions: Arthritis, Psoriatic

Summary: the purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (psa) and inadequate response (ir) and/or intolerance to a prior anti-tumor necrosis factor (tnf) by assessing the reduction in signs and symptoms of psa.

psa is a chronic, immune-mediated inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis. guselkumab is a fully human monoclonal antibody (mab) that binds to p19 protein subunit of interleukin (il)-23 and blocks the binding of extracellular il-23 to the cell surface il-23 receptor, inhibiting il-23 specific intracellular signaling, subsequent activation, and cytokine production. the primary hypothesis of this study is that guselkumab is superior to placebo as assessed by the proportion of participants who had an inadequate response (ir) and/or intolerance to one prior anti-tumor necrosis factor (anti-tnf) achieving an american college of rheumatology 20 (acr 20) response at week 24. this study will consist of a screening phase (up to 6 weeks), blinded treatment phase (approximately up to 2 years), which includes a placebo-controlled period from week 0 to week 24, and an active-controlled treatment phase from week 24 to week 100, and safety follow-up phase (week 112). safety assessments will include physical examinations, vital signs, height, weight, electrocardiograms, and clinical safety laboratory assessments. the total duration of the study will be up to 118 weeks.

Eligibility criteria:
inclusion criteria: * have a diagnosis of active psoriatic arthritis (psa) for at least 6 months before the first administration of study agent and meet classification criteria for psoriatic arthritis (caspar) at screening * have active psa as defined by: at least 3 swollen joints and at least 3 tender joints at screening and at baseline; and c-reactive protein (crp) greater than or equal to (\>=) 0.3 milligrams per deciliter (mg/dl) at screening from the central laboratory * have at least one of the following psa subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis * have active plaque psoriasis, with at least one psoriatic plaque of \>= 2 centimeters (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis * have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (tnf alpha) therapy, defined as presence of active psa despite previous treatment with one prior anti-tnf alpha agent exclusion criteria: * has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy in the treatment of psa, including but not limited to rheumatoid arthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemic lupus erythematosus, or lyme disease * has received more than 1 prior anti-tumor necrosis factor (tnf) alpha agent (or biosimilars) * has ever received janus kinase (jak) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational jak inhibitor * has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention * has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients * has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent urinary tract infection (example, recurrent pyelonephritis or chronic non-remitting cystitis), fungal infection (example, mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers